MedTrace Logo

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

NCT02052349 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-02-03

No results posted yet for this study

Summary

This open label, Phase 1 study is to investigate the relative bioavailability of ABT-333 when delivered within different sites of the gastrointestinal tract in 12 healthy subjects.

Conditions

  • Relative Bioavailability

Interventions

DRUG

ABT-333

Dose of ABT-333

Sponsors & Collaborators

Principal Investigators

  • Dan Cohen, MD · AbbVie

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052349 on ClinicalTrials.gov